Planned intervention: On Wednesday April 3rd 05:30 UTC Zenodo will be unavailable for up to 2-10 minutes to perform a storage cluster upgrade.
Published July 3, 2020 | Version 1.0.0
Dataset Open

HADDOCK pharmacophore-based screening against the COVID-19 main protease (Mpro)

  • 1. Utrecht University

Description

The novel coronavirus (SARS-CoV-2) that has emerged from Wuhan, China in December 2019 has spread to almost all countries in the world causing a dramatic number of deaths. The current absence of antiviral treatment against the SARS-CoV-2 urges the scientific community to accelerate the drug discovery research process.

One way to identify potential treatments and to be able to administer it swiftly is to focus on drug repurposing studies, i.e. to investigate the SARS-CoV-2 antiviral potential of drugs that have already been approved for human use.

Proteins that are crucial for the survival and replication of the virus are the most attractive targets for such studies. Here we have focused on the SARS-CoV-2 main protease (3CLpro) that plays an essential role in the virus replication process by screening ~2000 approved drugs (and 6 experimental ones) against this particular protein using a pharmacophore-based assay.

This is one part of a multi-target screen emphasising the main protease (Mrpo), the RNA-dependent-RNA-polymerase (RdRp) and human ACE2. The other datasets can found at the following locations:

More information about this screen along with interactive visualisations of the top compounds can be found on our website bonvinlab.org.

Files

Files (10.7 GB)

Name Size Download all
md5:307f4ce285e402fa7788cf26ab260535
10.7 GB Download

Additional details

Funding

BioExcel-2 – BioExcel Centre of Excellence for ComputationalBiomolecular Research 823830
European Commission
EOSC-hub – Integrating and managing services for the European Open Science Cloud 777536
European Commission